Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Servier buys development and commercialization rights of OSE’s Effi-7 French pharma Servier has acquired the exclusive global rights for development and commercialization of OSE Immunotherapeutics’ Effi-7 in a licence option deal that could worth €272m. News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Lilly's Trulicity label updated to include use in combination with basal insulin for type 2 diabetes
Eli Lilly and Company has updated label of its once-weekly Trulicity (dulaglutide) to include use in combination with basal insulin for adults with Type 2 diabetes.
Drug Research > Drug Delivery > News
US FTC sues Shire ViroPharma for delaying generic entry of Vancocin
By PBR Staff Writer
The US Federal Trade Commission (FTC) has charged that Shire ViroPharma abused government processes via serial, sham petitioning to delay generics and maintain its monopoly over Vancocin HCl Capsules.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Pharma Two B raises $30m for trial of Parkinson's treatment
Pharma Two B, a privately held biopharmaceutical firm engaged in the development of treatments for Parkinson’s disease, has closed $30m financing round.
Drug Research > Drug Discovery & Development > News
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News